Live

China, EU retaliate as Trump's massive tariffs kick in across the world. See the latest.

NasdaqCM - Nasdaq Real Time Price USD

Longeveron Inc. (LGVNR)

0.0005

-0.0003

(-37.50%)

As of September 21 at 3:51:25 PM EDT. Market Open.

No Tool

Measure

UNDO

Redo

All

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for LGVNR

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease

LGVN Announces Positive Alzheimer’s News

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s Disease

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s Disease

Longeveron® to Present at the 37th Annual Roth Conference

Longeveron® to Present at the 37th Annual Roth Conference

LGVN Well Positioned for Critical 2025

Analysts Expect Breakeven For Longeveron Inc. (NASDAQ:LGVN) Before Long

Analysts Expect Breakeven For Longeveron Inc. (NASDAQ:LGVN) Before Long

Longeveron Full Year 2024 Earnings: Beats Expectations

Longeveron Full Year 2024 Earnings: Beats Expectations

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025

Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025

Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™